Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Operating Cash Flow
Cash generated by the company's core business operations during the period.
Journey Medical CorporationNASDAQ: DERM
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $2.91M, compared with -$2.83M a year earlier. Trailing-twelve-month operating cash flow was -$6.78M. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Operating cash flow amounted to 20.1% of revenue in FY2025, up 3.9 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near $2.91M or moves back toward the trailing-twelve-month quarterly average of -$1.69M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (12.44M) USD
- Year-over-year change
- -36.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.44M) | -36.3% |
| FY2024 | 2024-12-31 | (9.13M) | -274.2% |
| FY2023 | 2023-12-31 | 5.24M | +138.7% |
| FY2022 | 2022-12-31 | (13.53M) | -520.5% |
| FY2021 | 2021-12-31 | (2.18M) | — |
Operating Cash Flow vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -2.4% is the 7th highest of 10, against a peer median of +17.5%.
- Operating cash flow amounts to 10.5% of revenue for DERM, versus a peer median of 166.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €100.98M EUR | +17.5% | +31.0% | 2252.6% | |
| LTM Mar 2026 | $72.97M USD | +136.4% | +32.7% | 4110.9% | |
| LTM Mar 2026 | €71.96M EUR | +29.7% | +32.9% | 441.0% | |
| LTM Mar 2026 | $54.52M USD | +0.8% | +18.7% | 166.6% | |
| LTM Mar 2026 | $43.19M USD | -4887.7% | -89.9% | 38.2% | |
| LTM Mar 2026 | $17.86M USD | +36.0% | +6.9% | 123.3% | |
| LTM Mar 2026 | $17.81M USD | +53.8% | +4.9% | 185.7% | |
| LTM Mar 2026 | CA$8.39M CAD | -46.2% | — | 3.1% | |
| LTM Mar 2026 | $6.78M USD | -2.4% | -2.8% | 10.5% | |
| LTM Mar 2026 | $5.78M USD | -64.7% | -11.6% | 11.3% | |
| Peer median (excluding DERM) | — | +17.5% | +12.8% | 166.6% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.